These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 33195370)

  • 1. Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients.
    Sahin E; Orhan C; Uckun FM; Sahin K
    Front Nutr; 2020; 7():580504. PubMed ID: 33195370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Nutritional Supports Beneficial in Other Viral Diseases Be Favorable for COVID-19?
    Zelka FZ; Kocatürk RR; Özcan ÖÖ; Karahan M
    Korean J Fam Med; 2022 Jan; 43(1):3-15. PubMed ID: 35130635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
    Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
    JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
    Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
    Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
    Noor R
    Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutrition as a key to boost immunity against COVID-19.
    Calcuttawala F
    Clin Nutr ESPEN; 2022 Jun; 49():17-23. PubMed ID: 35623808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
    Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
    Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.